JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. (Q54405988)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. |
scientific article |
Statements
JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. (English)
Emeline Evrot
Nicolas Ebel
Vincent Romanet
Claudia Roelli
Rita Andraos
Zhiyan Qian
Arno Dölemeyer
Ernesta Dammassa
Dario Sterker
Robert Cozens
Francesco Hofmann
Masato Murakami
Fabienne Baffert
Thomas Radimerski
30 September 2013
19
22
6230-6241